Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

After May 22, compounding pharmacies can no longer make and sell semaglutide injections. They were initially allowed to because the FDA declared a shortage, but that period has ended. At Melrose ...

The decision came in response to a February lawsuit from a compounding industry group against the FDA's decision that there ...

Novo Nordisk’s (NOVOb.CO), opens new tab diabetes medicine Rybelsus, an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular benefits as the injectable forms of the drug ...

Learn more › Ready to transform your body before summer? It’s possible with the ShedRx 4-Week Semaglutide Weight Loss Program. It offers personalized care, telehealth consultations ...

Semaglutide and related weight-loss medications, known as GLP-1 agonists, may slow biological ageing, reduce inflammation, improve cognitive function and gut health, and reduce alcohol use in people ...

Oral semaglutide 14 mg was associated with better cardiometabolic outcomes than active comparators, including empaglifozin and liraglutide, among patients with T2D. Oral semaglutide improves ...

A federal judge April 24 rejected a bid by compounding pharmacies to continue selling less expensive copies of semaglutide, Novo Nordisk's blockbuster drug sold under the brands Wegovy and Ozempic.

Come May 22, compounding pharmacies must stop making semaglutide injections, which serve as a more affordable generic alternative to Ozempic and Wegovy. This decision follows a judge's denial of ...

Semaglutide medications like Ozempic and Wegovy have exploded in popularity in recent years due to their effectiveness in diabetes control and weight loss. Research has revealed additional ...

A US judge has rejected efforts by a compounded drugs industry group to keep making an alternative version of Novo Nordisk’s popular drug semaglutide, opening the door for the US Food and Drug ...

The proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide ...